Medical device maker Stryker Corporation (SYK) entered a merger agreement on January 6, 2025, to acquire Inari Medical, Inc. (NARI) in an all-cash deal worth $4.9 billion.
Under the terms of the agreement, Stryker will commence a tender offer for all outstanding shares of Inari’s common stock for $80 per share in cash, representing a premium of 60.74% from the stock’s last close.
Inari is a medical device company that makes and sells tools to treat blood clots and other vein-related conditions, like deep vein thrombosis and pulmonary embolism.
Stryker is a medical technology company that creates devices and equipment for surgeries, joint replacements, and treatments for brain, spine, and vein-related conditions, helping improve healthcare and patient outcomes worldwide.
The acquisition of Inari strengthens Stryker’s efforts to expand its treatments for venous thromboembolism, a condition in which blood clots form in veins, and other vascular diseases.
The deal is expected to close by the end of the first quarter of 2025.
The acquisition price reflects 5.03 times the sales of Inari Medical.
For more comprehensive information regarding this merger and acquisition transaction, please visit the Deal Metrics page here:
Deal Metrics for the acquisition of Inari Medical, Inc. (NARI) by Stryker Corporation (SYK)
The Deal Metrics page for each merger or acquisition includes:
Disclaimer: Please do your own due diligence before buying or selling any securities mentioned in this article. We do not warrant the completeness or accuracy of the content or data provided in this article.
Editor’s Note: Baranjot Kaur contributed to this article